Silo Pharma
SILO
8 hedge funds and large institutions have $176K invested in Silo Pharma in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
14% more funds holding
Funds holding: 7 → 8 (+1)
0.02% more ownership
Funds ownership: 0.21% → 0.23% (+0.02%)
14% less capital invested
Capital invested by funds: $204K → $176K (-$27.9K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28.8K |
| 2 |
FIM
FWL Investment Management
Dallas,
Texas
|
+$149 |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$119 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$16.6K |
| 2 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$417 |
| 3 |
JP Morgan Chase
New York
|
-$410 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FAIM
1
Financial Advocates Investment Management
Olympia,
Washington
| $95.7K | -$417 | -14 | -0.4% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $26.7K | -$16.6K | -557 | -34% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $24.2K | +$28.8K | +967 | New |
|
4
State Street
Boston,
Massachusetts
| $20.6K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $8.17K | +$119 | +4 | +1% |
|
|
WIM
6
Westside Investment Management
Santa Monica,
California
| $157 | – | – | – |
|
|
FIM
7
FWL Investment Management
Dallas,
Texas
| $134 | +$149 | +5 | New |
|
8
Wells Fargo
San Francisco,
California
| $32 | – | – | – |
|
|
9
JP Morgan Chase
New York
| – | -$410 | -13 | Closed |
|
SILO Hedge Fund Activity: Q3 2023 in Review
8 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Silo Pharma (SILO) for Q3 2023, worth a combined $176K — down 14% from $204K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SILO positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $28.8K. The largest seller was Geode Capital Management, cutting an estimated $16.6K.
- 8 institutional investors held Silo Pharma (SILO) as of Q3 2023, up from 7 in Q2 2023.
- Funds reported $176K of Silo Pharma stock for Q3 2023, down 14% quarter-over-quarter.
- 2 funds opened new Silo Pharma positions in Q3 2023 and 1 closed out, a net change of +1 holder.
- The largest Silo Pharma buyer in Q3 2023 was Vanguard Group, an estimated $28.8K added.
- The largest Silo Pharma seller in Q3 2023 was Geode Capital Management, an estimated $16.6K sold.
Based on aggregated 13F filings for Q3 2023.